Drugs / SPOT-03
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07188012 | Aug 2025 → Dec 2026 expected | Duchenne muscular dystrophy | Shanghai Siponuoyin Biotechnology Co Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPOT-03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07188012 ↗ |
| Route | Intravenous | “SPOT-03 injection administered via IV infusion” NCT07188012 ↗ |